Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma, Inc. (VOR)
:VOR
VOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.13 - $3.29
Previous CloseN/A
Volume424.02K
Average Volume (3M)5.38M
Market Cap
$263.50M
Enterprise Value-$38.26K
Total Cash (Recent Filing)$200.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta4.26
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.56
Shares Outstanding126,683,110
10 Day Avg. Volume6,108,429
30 Day Avg. Volume5,378,850
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.18Price Target Upside-43.27% Downside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 clinical study for telitacicept in primary Sjögren's disease in China achieved the primary endpoint, showing improved disease activity and a favorable safety profile.
Financial PositionThe company reported cash, cash equivalents, and marketable securities of approximately $200.6M, which is believed to be sufficient to fund operations into 1Q27.
Licensing AgreementVor announced an exclusive license agreement with RemeGen Co., Ltd to develop and commercialize telitacicept in ex-Greater China geographies.
Bears Say
Financial PerformanceVor Bio reported a net loss of $12.56 per share for 2Q25, compared to the consensus estimated net loss of $2.92 per share.
Stock DowngradeThe stock has been downgraded to a Neutral rating due to the recent corporate update.
Workforce ReductionThe company is winding down all clinical and manufacturing operations, retaining only eight essential employees, leading to a workforce reduction of approximately 95%.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $0.13 and its highest was $3.29 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $263.50M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 202 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on Aug 07, 2025. The company reported -$12.562 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$12.302.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Overvalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 126,683,110 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of -$12.562 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -0.957%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.18 (-43.27% Downside)
$1.18 (-43.27% Downside)
Blogger Sentiment
Neutral
VOR Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
124.71%
12-Months-Change
Fundamentals
Return on Equity
-125.43%
Trailing 12-Months
Asset Growth
45.05%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$1.18
▼(-43.27% Downside)
Technical Analysis
Zentalis Pharmaceuticals
―
Pliant Therapeutics
―
C4 Therapeutics
―
Aziyo Biologics
―
Senti Biosciences
―
Ownership Overview
Currently, No data available
---